Clinical Trial Update: Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) [Phase 2]

View source ↗

Summary

A Phase 2 trial of SDX-101 (R-Etodolac) for relapsed or refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SDX-101 (R-Etodolac)

Snippet

Sponsor: Cephalon | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED